EP3508576A4 - MONOCLONAL ANTIBODIES AGAINST MILK AND USE THEREOF - Google Patents

MONOCLONAL ANTIBODIES AGAINST MILK AND USE THEREOF Download PDF

Info

Publication number
EP3508576A4
EP3508576A4 EP17846316.2A EP17846316A EP3508576A4 EP 3508576 A4 EP3508576 A4 EP 3508576A4 EP 17846316 A EP17846316 A EP 17846316A EP 3508576 A4 EP3508576 A4 EP 3508576A4
Authority
EP
European Patent Office
Prior art keywords
utilization
monoclonal antibody
antibody against
against melk
melk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17846316.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3508576A1 (en
Inventor
Yosuke Harada
Suyoun CHUNG
Yusuke Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of EP3508576A1 publication Critical patent/EP3508576A1/en
Publication of EP3508576A4 publication Critical patent/EP3508576A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
EP17846316.2A 2016-08-31 2017-08-25 MONOCLONAL ANTIBODIES AGAINST MILK AND USE THEREOF Pending EP3508576A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016169085 2016-08-31
PCT/JP2017/030443 WO2018043311A1 (ja) 2016-08-31 2017-08-25 Ｍｅｌｋに対するモノクローナル抗体およびその使用

Publications (2)

Publication Number Publication Date
EP3508576A1 EP3508576A1 (en) 2019-07-10
EP3508576A4 true EP3508576A4 (en) 2020-04-22

Family

ID=61301839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17846316.2A Pending EP3508576A4 (en) 2016-08-31 2017-08-25 MONOCLONAL ANTIBODIES AGAINST MILK AND USE THEREOF

Country Status (14)

Country Link
US (1) US11066477B2 (zh)
EP (1) EP3508576A4 (zh)
JP (1) JP7094557B2 (zh)
KR (1) KR102579047B1 (zh)
CN (1) CN109890963B (zh)
AU (1) AU2017318907B2 (zh)
BR (1) BR112019003408A2 (zh)
CA (1) CA3035160A1 (zh)
IL (1) IL264826B2 (zh)
MX (1) MX2019002269A (zh)
RU (1) RU2756982C2 (zh)
SG (2) SG10202100683RA (zh)
TW (1) TWI780067B (zh)
WO (1) WO2018043311A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536247A (ja) * 2019-06-07 2022-08-15 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152106A1 (en) * 2008-04-21 2011-06-23 Korea Research Institute Of Bioscience And Biotechnology Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer
EP2574929A1 (en) * 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker in diagnosing prostate cancer (PC)
US20150353935A1 (en) * 2013-01-11 2015-12-10 Novartis Ag MELK Regulation for the Treatment of Breast Cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP5087059B2 (ja) 2001-10-31 2012-11-28 杏林製薬株式会社 ４−（２−メチル−１−イミダゾリル）−２，２−ジフェニルブタンアミドの製造方法
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1651956A4 (en) 2003-08-14 2008-08-20 Exelixis Inc MELKS AS MODIFIERS OF THE ACTION ACTION MECHANISM AND METHODS OF USE
JP4721903B2 (ja) 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
JP5028601B2 (ja) 2004-08-10 2012-09-19 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
CN101283106A (zh) 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
AU2006315663A1 (en) 2005-11-10 2007-05-24 Exelixis, Inc. KIFS as modifiers of the RHO pathway and methods of use
WO2008023841A1 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
CA2806332C (en) 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
EP2753329B1 (en) 2012-01-19 2017-08-09 OncoTherapy Science, Inc. 1,5-naphthyridine derivatives as melk inhibitors
RU2504785C1 (ru) 2012-11-23 2014-01-20 Общество с ограниченной ответственностью "Синтавр" Способ диагностики рака молочной железы
EP3239295A4 (en) 2014-12-12 2018-10-31 Kyoto University Antibody highly specifically recognizing turn structure at 22- and 23-positions in amyloid beta

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152106A1 (en) * 2008-04-21 2011-06-23 Korea Research Institute Of Bioscience And Biotechnology Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer
EP2574929A1 (en) * 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker in diagnosing prostate cancer (PC)
US20150353935A1 (en) * 2013-01-11 2015-12-10 Novartis Ag MELK Regulation for the Treatment of Breast Cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "HPA017214 Anti-MELK antibody produced in rabbit", WWW.SIGMAALDRICH.COM, 1 January 2020 (2020-01-01), pages 1 - 4, XP055676030, Retrieved from the Internet <URL:https://www.sigmaaldrich.com/catalog/product/sigma/hpa017214?lang=en ion=NL> [retrieved on 20200312] *

Also Published As

Publication number Publication date
KR102579047B1 (ko) 2023-09-14
MX2019002269A (es) 2019-09-18
JPWO2018043311A1 (ja) 2019-06-24
JP7094557B2 (ja) 2022-07-04
EP3508576A1 (en) 2019-07-10
TWI780067B (zh) 2022-10-11
AU2017318907A2 (en) 2019-03-28
CA3035160A1 (en) 2018-03-08
RU2756982C2 (ru) 2021-10-07
IL264826B2 (en) 2024-06-01
IL264826B1 (en) 2024-02-01
US11066477B2 (en) 2021-07-20
BR112019003408A2 (pt) 2019-06-25
US20190185575A1 (en) 2019-06-20
RU2019107355A3 (zh) 2020-11-02
WO2018043311A1 (ja) 2018-03-08
SG10202100683RA (en) 2021-03-30
CN109890963B (zh) 2023-10-03
AU2017318907A1 (en) 2019-03-21
RU2019107355A (ru) 2020-10-01
TW201818972A (zh) 2018-06-01
AU2017318907B2 (en) 2023-07-06
KR20190043591A (ko) 2019-04-26
CN109890963A (zh) 2019-06-14
IL264826A (zh) 2019-04-30
SG11201901435UA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
IL290412B (en) New monoclonal antibodies to cd47 and their uses
EP3473649A4 (en) MONOCLONAL ANTI-CD47 ANTIBODIES AND USES THEREOF
IL262092A (en) Human anti-pacap antibodies and their use
EP3325513A4 (en) Anti-pd-l1 antibodies and uses thereof
EP3733704A4 (en) Anti-pd-l1 antibody and uses thereof
EP3532100A4 (en) ANTI-PD-L1 ANTIBODIES AND VARIANTS
EP3400243A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
IL282968A (en) Anti-NKG2A antibodies and their use
EP3363816A4 (en) ANTI-OX40 ANTIBODIES AND USES THEREOF
EP3587453A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
SG11202104240TA (en) Cll1-targeting antibody and application thereof
EP3181587A4 (en) Anti-human il-17 monoclonal antibody and use thereof
IL275826A (en) Anti-mct1 antibodies and their uses
EP3480216A4 (en) ANTI-PCSK9 MONOCLONAL ANTIBODIES
EP3612565A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3594241A4 (en) IL-13RA2 TARGETING ANTIBODY AND ITS APPLICATION
IL281297A (en) Anti-NPR1 antibodies and uses thereof
EP3567053A4 (en) MONOCLONAL ANTI-CLAUDIN-2 ANTIBODY
HK1246805A1 (zh) 抗flu b的廣譜單克隆抗體及其用途
EP3464355A4 (en) MONOCLONAL DSG2 ANTIBODIES AND USES THEREOF
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
EP3733706A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200319

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101ALI20200313BHEP

Ipc: G01N 33/574 20060101ALI20200313BHEP

Ipc: C07K 16/30 20060101ALI20200313BHEP

Ipc: C12N 15/09 20060101AFI20200313BHEP

Ipc: G01N 33/50 20060101ALI20200313BHEP

Ipc: C12P 21/02 20060101ALI20200313BHEP

Ipc: G01N 33/573 20060101ALI20200313BHEP

Ipc: C12Q 1/02 20060101ALI20200313BHEP

Ipc: G01N 33/15 20060101ALI20200313BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004366

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231016